EUVIMEDEUVIMED entdecken
Crossref

Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study

Omar Elkayal iD, Beatrijs Mertens iD, Joost Wauters iD, Yves Debaveye iD, Bart Rijnders iD, Paul E Verweij iD, Roger J Brüggemann iD, Isabel Spriet iD, Erwin Dreesen iD

Journal of Antimicrobial Chemotherapy · 01.07.2024 · 79 (7) · 1645-1656

DOI: 10.1093/jac/dkae160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 03.06.2024. Verfasst von Omar Elkayal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Invasive Pulmonary Aspergillosis, Triazoles, Critical Illness, Antifungal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Posaconazole is used for the prophylaxis and treatment of invasive fungal infections in critically ill patients. Standard dosing was shown to result in adequate attainment of the prophylaxis Cmin target (0.7 mg/L) but not of the treatment Cmin target (1.0 mg/L).

Objectives

To provide an optimized posaconazole dosing regimen for IV treatment of patients with invasive pulmonary aspergillosis in the ICU.

Methods

A population pharmacokinetics (popPK) model was developed using data from the POSA-FLU PK substudy (NCT03378479). Monte Carlo simulations were performed to assess treatment Cmin and AUC0–24 PTA. PTA ≥90% was deemed clinically acceptable. PopPK modelling and simulation were performed using NONMEM 7.5.

Results

Thirty-one patients with intensive PK sampling were included in the PK substudy, contributing 532 posaconazole plasma concentrations. The popPK of IV posaconazole was best described by a two-compartment model with linear elimination. Interindividual variability was estimated on clearance and volume of distribution in central and peripheral compartments. Posaconazole peripheral volume of distribution increased with bodyweight. An optimized loading regimen of 300 mg q12h and 300 mg q8h in the first two treatment days achieved acceptable PTA by Day 3 in patients <100 kg and ≥100 kg, respectively. A maintenance regimen of 400 mg q24h ensured ≥90% Cmin PTA, whereas the standard 300 mg q24h was sufficient to achieve the AUC0–24 target throughout 14 days, irrespective of bodyweight.

Conclusions

We have defined a convenient, optimized IV posaconazole dosing regimen that was predicted to attain the treatment target in critically ill patients with invasive aspergillosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Pulmonary AspergillosisTriazolesCritical IllnessAntifungal AgentsMonte Carlo MethodHumansFemaleMiddle AgedMaleAgedAdultAdministration, IntravenousComputer SimulationIntensive Care Units

Substanzen

posaconazoleTriazolesAntifungal Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Pharmacy Department, UZ Leuven, Leuven, Belgium.
  • Medical Intensive Care Unit, UZ Leuven, Leuven, Belgium.
  • Laboratory for Clinical Infectious and Inflammatory Disorders, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium.

ORCID-Profile: Omar Elkayal, Beatrijs Mertens, Joost Wauters, Yves Debaveye, Bart Rijnders, Paul E Verweij, Roger J Brüggemann, Isabel Spriet, Erwin Dreesen

Zitieren

APA

Elkayal, O., Mertens, B., Wauters, J., Debaveye, Y., Rijnders, B., Verweij, P. E., Brüggemann, R. J., Spriet, I., & Dreesen, E. (2024). Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. Journal of Antimicrobial Chemotherapy, 79(7), 1645-1656. https://doi.org/10.1093/jac/dkae160

Vancouver

Elkayal O, Mertens B, Wauters J, Debaveye Y, Rijnders B, Verweij PE, et al. Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. Journal of Antimicrobial Chemotherapy. 2024;79(7):1645-1656. doi:10.1093/jac/dkae160

BibTeX
@article{Elkayal2024,
  author = {Elkayal, Omar and Mertens, Beatrijs and Wauters, Joost and Debaveye, Yves and Rijnders, Bart and Verweij, Paul E and Brüggemann, Roger J and Spriet, Isabel and Dreesen, Erwin},
  title = {Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {7},
  pages = {1645--1656},
  doi = {10.1093/jac/dkae160}
}
Kostenlos starten →